Mirae Asset Global ETFs Holdings
KROS icon

Mirae Asset Global ETFs Holdings’s Keros Therapeutics KROS Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$91.1K Sell
8,511
-5,380
-39% -$59.9K ﹤0.01% 2870
2026
Q1 		$153K Sell
13,891
-1,426
-9% -$22K ﹤0.01% 2482
2025
Q4 		$312K Sell
15,317
-2,824
-16% -$49.5K ﹤0.01% 2137
2025
Q3 		$287K Buy
+18,141
New +$268K ﹤0.01% 2130
2025
Q2 		– Sell
-22,166
Closed -$227K – 3131
2025
Q1 		$227K Buy
22,166
+2,982
+16% +$34.6K ﹤0.01% 2260
2024
Q4 		$303K Buy
19,184
+1,386
+8% +$72K ﹤0.01% 2163
2024
Q3 		$1.03M Buy
17,798
+2,615
+17% +$129K ﹤0.01% 1524
2024
Q2 		$692K Buy
+15,183
New +$816K ﹤0.01% 1660

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's KROS Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings reduced its Keros Therapeutics (KROS) stake by 39% in Q2 2026, selling an estimated $59.9K and leaving 8,511 shares worth $91.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2870.

Mirae Asset Global ETFs Holdings first reported a position in KROS in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.03M in Q3 2024. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Mirae Asset Global ETFs Holdings held 8,511 shares of Keros Therapeutics worth $91.1K as of Q2 2026.
  • Mirae Asset Global ETFs Holdings sold 5,380 Keros Therapeutics shares in Q2 2026, an estimated $59.9K.
  • Keros Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #2870 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in Keros Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Mirae Asset Global ETFs Holdings's Keros Therapeutics position peaked at $1.03M in Q3 2024.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.